FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255350149> ?p ?o ?g. }

• W4255350149 endingPage "9035" @default.
• W4255350149 startingPage "9035" @default.
• W4255350149 abstract "9035 Background. Results of CT in MSTS remain disappointing. Only 3 agents are active (Adriamycin, Ifosfamide, Deticene) with RR of 16–25% as single agent and 20–40% in poliCT. The 2nd line is more frustrating. The same drugs at different doses or schedules therapy offer 10–15% objective responses, TTP of 3–4 months and MS of 10–12 months. HDI (12–16 g/m2) on continuous intravenous infusion has demonstrated significant antitumor activity. Two different schedules have been published: 4 days c.i. (Le Cesne, JCO 1995) and 14 days c.i. (Frustaci & Comandone Proc ASCO 1998) with the same total dose of 14 g/m2. Methods. We treated from 1996 to 2003 90 pts with pretreated MSTS using both schedules. We report the results of the two protocols as perspective phase II trials independently analyzed. 90 pts with measurable MSTS previously treated with Antracyclines entered the study. Both sexes, age from 18 to 70 years, histological demonstration, PS 0–2 ECOG, good renal and hematological function, informed consent were requested. Protocol A): 54 pts treated with HDIFO in 4 days c.i. (3,5 g/m2/d + Mesna equidose). Protocol B): 36 pts received IFO 1 g/m2/d c.i. for 14 days + Mesna equidose). The two schedules were repeated every 21–28 days following the complete recovery from toxicities. Leiomiosarcomas, MFH, Synovialsarcomas and Liposarcomas were the most represented histological types. Lung and local failure were the two most common sites of relapse. Results. In protocol A Neutropenia G3/G4 (100%), Thrombocytopenia G3/G4 (30%), Anemia (28%), Alopecia G3 (100%), N&V G3 (28,4%) and Ipokaliemia (17%) were the most common toxicities. In protocol B Neutropenia G3/G4 (7%), N&V G3 (5%) were the most serious adverse effects. In protocol A 6 RR (12%, 1 CR) and 11 SD (22,4%) were recorded; TTP 6,7 mo, MS 12 mo. In protocol B 4 RR (12%, 1CR) and 9 SD (27%) were seen, TTP 4,2 mo, MS 10,4 mo. Conclusions. The activity of HDI in pretreated MSTS suggests a dose response relationship. Both protocols guarantee a percentage of RR not exceeding 12%. Maintained SD in about 25% of the pts must be considered a positive result in 2nd line CT for MSTS. HDI in 4 days c.i. seems to be more toxic. No significant financial relationships to disclose." @default.
• W4255350149 created "2022-05-12" @default.
• W4255350149 creator A5000427216 @default.
• W4255350149 creator A5022902000 @default.
• W4255350149 creator A5033483931 @default.
• W4255350149 creator A5036831532 @default.
• W4255350149 creator A5039982719 @default.
• W4255350149 creator A5045271452 @default.
• W4255350149 creator A5079496281 @default.
• W4255350149 creator A5081161436 @default.
• W4255350149 creator A5086466665 @default.
• W4255350149 creator A5087214212 @default.
• W4255350149 date "2004-07-15" @default.
• W4255350149 modified "2023-09-26" @default.
• W4255350149 title "Metastatic soft tissue sarcomas (MSTS): Second line chemotherapy (CT) using two different schedules of high dose ifosfamide (HDI)" @default.
• W4255350149 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.9035" @default.
• W4255350149 hasPublicationYear "2004" @default.
• W4255350149 type Work @default.
• W4255350149 citedByCount "0" @default.
• W4255350149 crossrefType "journal-article" @default.
• W4255350149 hasAuthorship W4255350149A5000427216 @default.
• W4255350149 hasAuthorship W4255350149A5022902000 @default.
• W4255350149 hasAuthorship W4255350149A5033483931 @default.
• W4255350149 hasAuthorship W4255350149A5036831532 @default.
• W4255350149 hasAuthorship W4255350149A5039982719 @default.
• W4255350149 hasAuthorship W4255350149A5045271452 @default.
• W4255350149 hasAuthorship W4255350149A5079496281 @default.
• W4255350149 hasAuthorship W4255350149A5081161436 @default.
• W4255350149 hasAuthorship W4255350149A5086466665 @default.
• W4255350149 hasAuthorship W4255350149A5087214212 @default.
• W4255350149 hasConcept C126322002 @default.
• W4255350149 hasConcept C126838900 @default.
• W4255350149 hasConcept C136948725 @default.
• W4255350149 hasConcept C142724271 @default.
• W4255350149 hasConcept C143998085 @default.
• W4255350149 hasConcept C2776694085 @default.
• W4255350149 hasConcept C2777506904 @default.
• W4255350149 hasConcept C2778239845 @default.
• W4255350149 hasConcept C2778256501 @default.
• W4255350149 hasConcept C71924100 @default.
• W4255350149 hasConceptScore W4255350149C126322002 @default.
• W4255350149 hasConceptScore W4255350149C126838900 @default.
• W4255350149 hasConceptScore W4255350149C136948725 @default.
• W4255350149 hasConceptScore W4255350149C142724271 @default.
• W4255350149 hasConceptScore W4255350149C143998085 @default.
• W4255350149 hasConceptScore W4255350149C2776694085 @default.
• W4255350149 hasConceptScore W4255350149C2777506904 @default.
• W4255350149 hasConceptScore W4255350149C2778239845 @default.
• W4255350149 hasConceptScore W4255350149C2778256501 @default.
• W4255350149 hasConceptScore W4255350149C71924100 @default.
• W4255350149 hasIssue "14_suppl" @default.
• W4255350149 hasLocation W42553501491 @default.
• W4255350149 hasOpenAccess W4255350149 @default.
• W4255350149 hasPrimaryLocation W42553501491 @default.
• W4255350149 hasRelatedWork W2003208630 @default.
• W4255350149 hasRelatedWork W2013276093 @default.
• W4255350149 hasRelatedWork W2013312714 @default.
• W4255350149 hasRelatedWork W2028517250 @default.
• W4255350149 hasRelatedWork W2065910438 @default.
• W4255350149 hasRelatedWork W2139550043 @default.
• W4255350149 hasRelatedWork W2368332383 @default.
• W4255350149 hasRelatedWork W2391581375 @default.
• W4255350149 hasRelatedWork W2428528889 @default.
• W4255350149 hasRelatedWork W1993277780 @default.
• W4255350149 hasVolume "22" @default.
• W4255350149 isParatext "false" @default.
• W4255350149 isRetracted "false" @default.
• W4255350149 workType "article" @default.